Regulation 30 Disclosure - Entry into the Urology Therapy Segment

Aptus Pharma has announced its entry into the Urology therapy segment as part of its business expansion plans. The company will launch a new portfolio including Silodosin, Tamsulosin, and Alkalizer formulations, supported by its existing field-sales force and a distribution network of 150+ distributors and sub-distributors across India. Management expects this new portfolio to meaningfully contribute to future revenue and profitability. The Indian urology market is highlighted as one of the fastest-growing chronic therapy segments, expanding at roughly 9-10% annually. Managing Director Tejash Hathi stated that this move strengthens the company's specialty-care capabilities and positions it for sustained long-term growth.